Researchers from The University of Western Australia have developed a winning medicine formula that makes bad-tasting medicine taste nice, making it easier to treat sick children.
The UWA study published by the journal Anaesthesia tested 150 children and found that the majority of children who were given the new chocolate-tasting medicine would take it again, unlike the standard treatment, while they still experienced the same beneficial effects.
UWA Clinical Senior Lecturer Dr Sam Salman said the poor taste of many medicines, such as Midazolam, a sedative used prior to surgery, presented a real difficulty in effectively treating children.
A Macquarie University start-up that created a new way to develop drugs faster and more cheaply than current methods, has won a CSIRO innovation award.
Currently it takes over a decade and $2 billion to develop a new drug. Of these, four out of five will never be launched.
If we want everyone in need to have access to affordable and effective medications, we must reduce the time and cost associated with drug development, argues Molecular Sciences’ Professor Peter Karuso.
The idea that long-term memory might be stored in our brain’s DNA is being tested by Professor Geoff Faulkner, using brains affected by Alzheimer’s.
Geoff has already shown that the DNA in our brains is different to the DNA in the rest of our bodies and that it changes as we learn. He’s proposing that these changes are associated with how we store our long-term memories.
More recently, he’s linked these differences to the function of genes in the hippocampus, the part of the brain that controls memory and spatial navigation, and has been implicated in memory loss with ageing, schizophrenia and Alzheimer’s disease. Continue reading Are memories stored in DNA?→
Today, 85 per cent of children with leukaemia can be cured, but the outlook for patients over 60 is bleak. Only 10 per cent survive beyond one year as their cancer adapts to weather the storm of standard chemotherapy treatments. Associate Professor Steven Lane wants to change that outlook.
Steven and his team at the QIMR Berghofer Medical Research Institute have developed a method to rapidly profile the genetics of different leukaemia types—of which there are hundreds—and model them in the lab.
Professor Mark Kendall is planning to dispatch the 160-year-old needle and syringe to history. He’s invented a new vaccine technology that’s painless, uses a fraction of the dose, puts the vaccine just under the skin, and doesn’t require a fridge.
The Nanopatch is a 1 cm square piece of silicon with 20,000 microscopic needles engineered on one side. Coat the needles with dry vaccine, push it gently but firmly against the skin, and the vaccine is delivered just under the outer layer of skin.
It’s a technology he invented in response to a call from the Bill and Melinda Gates Foundation seeking ideas for delivery of vaccines in developing countries—where it’s a challenge to keep conventional wet vaccines cold to the point of delivery.
Cancer is the leading cause of death among people with HIV and yet cancer treatment can be risky as their immune system is already compromised.
Now, a new class of drugs developed at the Kirby Institute at the University of New South Wales is providing hope—demonstrating it is effective in treating the cancer and strengthening the immune response to that cancer.